← Calendar
Readoutin 104d
Novartis Pharmaceuticals — Ianalumab
Phase 3 primary completion: Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1).
- Date
- Mar 2027
- Type
- Readout
- Indication
- Systemic Lupus Erythematosus
Source ↗Add to calendar
Get told when this date moves
The weekly brief is free. Pro adds reminders 7 days and 1 day before.
More from Novartis Pharmaceuticals
May2027
Readoutin 165d
Novartis Pharmaceuticals — Inclisiran sodium 300 mgPhase 3 primary completion: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease.
Apr2027
Readoutin 135d
Novartis Pharmaceuticals — IanalumabPhase 3 primary completion: Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1).